tert-butyl (3-aminopentyl)carbamate | 210240-75-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (3-aminopentyl)carbamate
• 英文别名: (3-aminopentyl)carbamic acid tert-butyl ester；1,1-dimethylethyl (3-aminopentyl)carbamate；tert-butyl N-(3-aminopentyl)carbamate
• CAS: 210240-75-8
• 化学式: C₁₀H₂₂N₂O₂
• 分子量: 202.297
• InChiKey: NMZBDDOBSIZYCI-UHFFFAOYSA-N

物化性质

• 沸点：
  299.5±23.0 °C(Predicted)
• 密度：
  0.963±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2921290000

反应信息

• 作为反应物：
  描述：

  tert-butyl (3-aminopentyl)carbamate 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 42.0h， 生成 N¹-(1-adamantylmethyl)-N³-(7-chloroquinolin-4-yl)pentane-1,3-diamine
  参考文献：
  名称：

  Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

  摘要：

  The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 mu M and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 mu M). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 +/- 0.37 mu M). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b01374
• 作为产物：
  描述：

  叔丁基苯基碳酸酯 、 1,3-二氨基戊烷 以 乙醇 为溶剂， 反应 4.0h， 以100%的产率得到tert-butyl (3-aminopentyl)carbamate
  参考文献：
  名称：

  [EN] SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE
  [FR] AMINO-BENZIMIDAZOLES SUBSTITUÉS, MÉDICAMENTS COMPRENANT LEDIT COMPOSÉ, LEUR UTILISATION ET LEUR PROCÉDÉ DE FABRICATION

  摘要：

  本发明涉及一般式（1）中的取代氨基苯并咪唑，其中基团R1至R14和A如规范和索赔中定义，并其用于治疗阿尔茨海默病（AD）和类似疾病。

  公开号：

  WO2009092566A1

文献信息

• [EN] SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE<br/>[FR] AMINO-BENZIMIDAZOLES SUBSTITUÉS, MÉDICAMENTS COMPRENANT LEDIT COMPOSÉ, LEUR UTILISATION ET LEUR PROCÉDÉ DE FABRICATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009092566A1

  公开（公告）日：2009-07-30

  The present invention relates to substituted amino-benzimidazoles of general formula (1) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

  本发明涉及一般式（1）中的取代氨基苯并咪唑，其中基团R1至R14和A如规范和索赔中定义，并其用于治疗阿尔茨海默病（AD）和类似疾病。
• Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors
  申请人：Bosch Michael

  公开号：US20080269170A1

  公开（公告）日：2008-10-30

  The disclosure relates to compounds of formula (I): wherein R1-R5, A and Y are as defined in the disclosure, to compositions comprising said compounds, and to processes for making and methods of using the same.

  该披露涉及到式(I)的化合物：其中R1-R5、A和Y如披露中所定义，以及包含该化合物的组合物，以及制备该化合物的方法和使用该化合物的方法。
• Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
  申请人：Elanco Animal Health Ireland Limited

  公开号：EP2487176A1

  公开（公告）日：2012-08-15

  This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

  这项发明涉及一种用于治疗或预防猫免疫缺陷病毒（FIV）的式（I）的萘啶衍生物。此外，本发明涉及一种治疗或预防猫免疫缺陷病毒感染的方法，其中该方法包括向该猫动物投予一种萘啶衍生物的治疗有效量。
• Acyclic 1,3-Diamine And Uses Therefor
  申请人：Casillas N. Linda

  公开号：US20070259965A1

  公开（公告）日：2007-11-08

  This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted amino-azepines, according to Formula I or pharmaceutically acceptable salts, hydrates, or solvates thereof, wherein: R 1 is aryl optionally substituted with CN, NO 2 , halogen or H; R 2 is H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, or C 3 -C 7 heterocycloalkyl; R 3 is H, OH, O—C 1 -C 6 alkyl, SH, S—C 1 -C 6 alkyl, or F; R 4 is H, C 1 -C 6 alkyl R 5 is iso-butyl, cyclohexylmethyl, or cyclopentylmethyl; and R 6 is aryl, heteroaryl.

  本发明涉及一种新型化合物，可用于治疗与TRPV4通道受体相关的疾病。更具体地说，本发明涉及按照公式I或其药学上可接受的盐、水合物或溶剂化物所替代的氨基-氮杂环化合物，其中：R1是芳基，可选用CN、NO2、卤素或H进行取代；R2是H、C1-C6烷基、C3-C7环烷基或C3-C7杂环烷基；R3是H、OH、O-C1-C6烷基、SH、S-C1-C6烷基或F；R4是H或C1-C6烷基；R5是异丁基、环己基甲基或环戊基甲基；R6是芳基或杂芳基。
• MACROCYCLIC INTEGRASE INHIBITORS
  申请人：Thuring Johannes Wilhelmus J

  公开号：US20120172367A1

  公开（公告）日：2012-07-05

  Compound having formula (I), wherein —W is NH—, —N(CH 3 )— or piperazine, —X is a bond, —C(═O)— or S(═O) 2 —, —Y is C 3-7 alkylene, and —Z is NH—C(═O)— or —O—, and pharmaceutically acceptable salts thereof, their pharmaceutical formulations and use as HIV inhibitors.

  具有式(I)的化合物，其中-W是NH-，-N(CH3)-或哌嗪，-X是键，-C(═O)-或S(═O)2-，-Y是C3-7烷基，-Z是NH-C(═O)-或-O-，以及其药学上可接受的盐，其制药配方和用作HIV抑制剂。